Loading clinical trials...
Loading clinical trials...
Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine in Healthy Adults Aged 18 to 49 Years
Conditions
Interventions
FluBlok®
Placebo
Locations
24
United States
Impact Clinical Trials
Beverly Hills, California, United States
Benchmark Research - Sacramento
Sacramento, California, United States
Benchmark Research - San Francisco
San Francisco, California, United States
University Clinical Research, Inc
Pembroke Pines, Florida, United States
Vince and Associates
Overland Park, Kansas, United States
Kentucky pediatric /Adult Research
Bardstown, Kentucky, United States
Start Date
September 15, 2007
Primary Completion Date
May 28, 2008
Completion Date
May 28, 2008
Last Updated
April 6, 2022
NCT01386424
NCT07169318
NCT07291635
NCT06599658
NCT06094010
NCT06753474
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions